98%
921
2 minutes
20
Background/objectives: Extrahepatic recurrence (EHR) is a significant negative prognostic factor in hepatocellular carcinoma (HCC). Although EHR is commonly observed in high-risk patients following HCC hepatectomy, its occurrence without concurrent intrahepatic HCC remains poorly understood. Therefore, this study aims to examine the clinical characteristics and risk factors associated with EHR in patients without intrahepatic HCC at diagnosis.
Methods: This study included 1066 treatment-naïve patients who underwent curative hepatectomy for HCC at four tertiary academic centers between January 2004 and December 2019. After excluding those with intrahepatic recurrence (IHR), concurrent EHR, or incomplete clinical records, 569 patients were included in the final analysis. Risk factors for EHR were assessed using multivariate Cox regression over a median follow-up period of 3.91 years.
Results: Among the cohort, 38 patients developed EHR post-surgery without residual intrahepatic HCC, with a median follow-up of 1.04 years. These patients experienced earlier initial HCC recurrence than those without EHR (1.73 vs. 4.43 years). Multivariate analysis revealed significant associations between EHR and microvascular invasion (hazard ratio [HR]: 2.418, = 0.020), tumor necrosis (HR: 2.592, = 0.009), and initial tumor staging beyond the Milan criteria (HR: 3.008, = 0.001). Moreover, Cox regression analysis revealed that EHR strongly correlated with decreased post-hepatectomy survival (HR: 14.044, < 0.001). Cumulative EHR and survival rates were closely linked to the number of risk factors present.
Conclusions: EHR without detectable IHR is significant and warrants close monitoring in high-risk patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070905 | PMC |
http://dx.doi.org/10.3390/cancers17091417 | DOI Listing |
Glob Health Med
August 2025
National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Liver resection (LR) remains a cornerstone curative option for patients with hepatocellular carcinoma (HCC), and yet the high rate of postoperative intrahepatic recurrence poses a significant clinical challenge. Despite numerous attempts, no adjuvant therapy has shown definitive efficacy in preventing recurrence. In this context, salvage liver transplantation (SLT) and repeat hepatectomy (RH) have emerged as key curative strategies for recurrent disease.
View Article and Find Full Text PDFSignal Transduct Target Ther
September 2025
Interventional Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
The objective response rate of conventional transarterial chemoembolization (TACE) for locoregional control of hepatocellular carcinoma (HCC) is approximately 50%. We previously developed bicarbonate-integrated TACE, termed TILA-TACE, which demonstrated 100% effectiveness for locoregional control of unresectable HCC. This study aimed to validate its efficacy, selectivity, and safety in real-world clinical practice (ChiCTR-ONC-17013416).
View Article and Find Full Text PDFIn Vivo
August 2025
Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Türkiye.
Background/aim: Cholangiocarcinoma (CCA) is the second most frequently occurring primary malignant tumor of the liver, characterized by poor survival due to late diagnosis and limited treatment options. The albumin-bilirubin (ALBI) and platelet-ALBI (PALBI) scores, which reflect liver function and inflammation, have emerged as potential prognostic markers in hepatocellular carcinoma (HCC). Their prognostic significance in CCA, however, remains less established.
View Article and Find Full Text PDFLiver Int
September 2025
Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background And Aims: The relationship between chronic liver disease and liver cancer remains poorly understood, and treatment options for advanced liver disease remain limited. This study aims to elucidate the dynamic evolution of cellular and molecular alterations from normal liver to diseased liver.
Methods: Single-cell RNA sequencing was performed to profile the dynamic cellular variations from normal liver to diseased liver.
Genes (Basel)
July 2025
Cell and Tissue Biology Group, Anatomy and Cell Biology Department, University of Cantabria-IDIVAL, 39011 Santander, Spain.
Hepatic cancers, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), are major global health concerns due to rising incidence and limited therapeutic success. While traditional risk factors include chronic liver disease and environmental exposures, recent evidence underscores the significance of genetic alterations and gut microbiota in liver cancer development and progression. This review aims to integrate emerging knowledge on the interplay between host genomic changes and gut microbial dynamics in the pathogenesis and treatment of hepatic cancers.
View Article and Find Full Text PDF